文献速递前列腺癌

ProtecT试验:筛状阳性与阴性前列腺癌根治性前列腺切除术后15年结局

Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial.
PubMed 文献 · BJU Int · 2026-03-27

基于ProtecT试验480例根治性前列腺切除术标本的中枢病理复核,筛状阳性(含浸润性筛状和/或导管内癌)143例(30%),筛状阴性337例(70%)。全部21例转移或致死事件仅见于筛状阳性组(15年累积发生率14%),风险集中于pT3b和/或GG≥3者(27%)。

要点

  • 筛状阳性者15年转移或死亡风险为14%,筛状阴性者为0。
  • 筛状阳性伴pT3b和/或GG≥3者15年事件率27%,为辅助治疗试验目标人群。
  • 筛状阳性但GG2且≤pT3a者15年事件率仅3%,支持多数患者降级管理。

核心结论

  • 根治性前列腺切除术后15年转移或死亡风险由筛状状态二元界定,筛状阳性者风险集中于高级别和/或pT3b肿瘤。

研究设计与样本

  • ProtecT 3期试验(NCT02044172)次要分析,1999–2009年入组1643例临床局限前列腺癌随机分主动监测、根治性前列腺切除术或放疗。
  • 对480例根治性前列腺切除术标本行中枢病理复核,按浸润性筛状癌和/或导管内癌分为筛状阳性与阴性。
  • 主要结局为转移进展或前列腺癌死亡的复合终点,采用多变量Cox回归评估15年风险,Gray检验比较累积发生率曲线。

主要发现

  • 480例复核标本中筛状阳性143例(30%),筛状阴性337例(70%)。
  • 全部21例转移或致死事件仅见于筛状阳性组,15年累积发生率14%。
  • 筛状阳性队列中,pT3b和/或GG≥3者15年累积发生率27%。
  • 筛状阳性患者多变量分析中,pT3b期(HR 8.19,95%CI 2.39–28.10;P<0.001)与GG3(HR 5.12,95%CI 1.59–16.40;P=0.006)为不良结局独立预测因素。
  • 筛状阳性且GG2、≤pT3a者15年事件率仅3%。

关键数值与推荐

  • 筛状阳性定义:存在浸润性筛状癌和/或导管内癌。
  • 筛状阳性组15年转移或死亡累积发生率14%,筛状阴性组0%。
  • 筛状阳性伴pT3b和/或GG≥3者15年累积发生率27%。
  • 筛状阳性伴GG2且≤pT3a者15年事件率3%。

临床怎么用

  • 根治性前列腺切除术后病理应常规报告筛状状态,以识别15年转移或死亡风险分层。
  • 筛状阳性且pT3b和/或GG≥3者风险最高,可考虑纳入辅助治疗临床试验。
  • 筛状阳性但GG2且≤pT3a者事件率低,支持对多数根治性前列腺切除术后患者降级管理。

局限性

  • 为ProtecT试验的回顾性次要分析,仅纳入480例有可用根治性前列腺切除术病理切片者。
  • 筛状状态基于中枢病理复核,未报告复核者间一致性。
  • 事件数少(21例),多变量模型估计精度有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To retrospectively analyse the results of the Prostate Testing for Cancer and Treatment (ProtecT; ClinicalTrials.gov identifier: NCT02044172) trial to establish the association between cribriform-positive and -negative prostate cancer (PCa) and the 15-year risk of metastasis or death from PCa in patients who underwent radical prostatectomy (RP). PATIENTS AND METHODS: Between 1999 and 2009, the ProtecT phase 3 clinical trial enrolled 1643 men with clinically localised PCa who were randomised to receive active monitoring, RP, or radiotherapy. In this secondary analysis of the trial, a centralised histopathological review was conducted on available RP pathology slides to classify patients as cribriform-positive if they had invasive cribriform carcinoma and/or intraductal carcinoma. The primary outcome was a composite of progression to metastatic disease or death from PCa. Exposures included age, prostate-specific antigen density, RP Grade Group (GG), pathological T stage (pT), and cribriform status. Multivariable Cox proportional hazards regression models assessed 15-year risk. Cumulative incidence curves were compared using the Gray test. RESULTS: Of 480 men with RP specimens reviewed, 143 (30%) had cribriform-positive disease and 337 (70%) had cribriform-negative disease. All 21 metastatic or lethal events occurred exclusively in the cribriform-positive group (15-year cumulative incidence 14%). Within the cribriform-positive cohort, risk was concentrated in patients with pT3b stage and/or GG ≥3 (15-year cumulative incidence 27%). In multivariable analysis of cribriform-positive patients, pT3b stage (hazard ratio [HR] 8.19, 95% confidence interval [CI] 2.39-28.10; P < 0.001) and GG 3 disease (HR 5.12, 95% CI 1.59-16.40; P = 0.006) were independent predictors of adverse outcomes. Conversely, cribriform-positive patients with GG 2 and ≤pT3a had a 15-year event rate of only 3%. CONCLUSION: In the ProtecT trial, the 15-year risk of metastasis or death after RP was a binary outcome defined by cribriform status. The concentration of risk in men with cribriform-positive, high-grade and/or pT3b tumours identifies a target population for adjuvant therapy trials, while supporting management de-escalation for most RP patients.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Sushentsev N, Warren AY, Colling R, et al. Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial. BJU Int. 2026. PMID: 41896701. doi:10.1111/bju.70261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。